Trumps April 2026 Order on Psychedelic Mental Health Research

President Donald Trump signed an executive order on April 18, 2026 that he said “directs the FDA to expedite their review of certain psychedelics already designated as breakthrough therapy drugs.” A primary objective of the order is to speed treatment for veterans.
“The executive order I’m signing, we’re actually signing the executive order today, is really a moment,” Trump said. “These treatments are currently in the advanced stages of clinical trials to ensure that they’re both safe and effective for the American patients.”
The president said the executive order would implement “historic reforms to dramatically accelerate access to new medical research and treatments based on psychedelic drugs.” Citing the elevated veteran suicide rate, the president added: “In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression, including our cherished veterans.”
“And the nice part is we’re actually doing this early, but it has been going on. Research has been going on for quite some time. But, you know, usually with things like this, nothing ever happens, no matter how the research ends up, but we’re changing that. This order will clear away unnecessary bureaucratic hurdles, improve data sharing among the FDA and the Department of Veterans Affairs, and facilitate fast rescheduling of any psychedelic drugs that become FDA approved,” Trump continued.
The president said “in 2024, a study from Stanford University, 30 special operation veterans with traumatic brain injuries underwent — it’s called ibogaine treatment — ibogaine, remember the name,” noting that they “experienced an 80 to 90% reduction in symptoms of depression and anxiety within one month.”
“In Texas, Republican leaders have already committed $50 million to the ibogaine research. And today, the federal government is making a $50 million research investment in its own. And so that was just approved just last night,” Trump announced.
“We’re also opening a pathway for ibogaine to be administered to desperately ill patients under the right to try law,” Trump said.
“Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life, just lead a happier life,” he added.
The order concerns research and regulatory review. Expedited review still requires evaluation of a treatment's safety and effectiveness; it does not establish that every experimental psychedelic is an approved medicine. The president's remarks described treatments in clinical trials, an important distinction for patients considering what the announcement means for access to care.
The White House described a coordinated effort involving the Food and Drug Administration, the Department of Veterans Affairs, and other federal agencies. Its stated aim was to move promising research through existing oversight pathways more efficiently. The Right to Try provision concerned eligible patients and investigational access, while the research investment was intended to support further study. Those are separate steps from routine prescribing, and the announcement should be understood in that research context.
The announcement placed veterans at the center of the research effort, while describing a regulatory process that would continue after the signing ceremony.